Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Biosciences Seeks to Change Name to Orchid Cellmark

NEW YORK, April 14 (GenomeWeb News) - Orchid Biosciences is seeking stockholder approval to change its name to Orchid Cellmark to reflect the company's positioning as a provider of DNA identity testing services, the firm said yesterday.

Shareholders will consider the name change at the Princeton, NJ-based company's annual stockholders meeting on June 8.

The new name would reflect the Cellmark DNA testing services unit, AstraZeneca's UK genetic testing subsidiary that Orchid acquired in 2001.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.